Uterine fibroids are the commonest tumour of the female reproductive tract, affecting almost 30% of women in their reproductive years. Fibroids are the most frequent reason for hysterectomy in premenopausal women. It is difficult to obtain Australian estimates of the cost of fibroid disease, but in the United States more than $2 billion is spent in annual hospital charges alone. Uterine fibroids have also been associated with infertility.

Symptoms of fibroid disease
Symptoms associated with fibroids have a significant impact on quality of life. Uterine fibroids cause symptoms through a mass effect: frequency, urgency and/or constipation, swelling/bloating, sciatica; and through abnormal uterine bleeding, dysmenorrhea, menorrhagia, and anaemia. Uterine fibroids have also been associated with infertility.

Medical and surgical treatment options
Each treatment option for fibroid disease has advantages and disadvantages. One of the major decisions that a woman needs to make when considering treatment options is whether she would prefer to keep her uterus.

Uterus removal
The traditional treatment for fibroids is hysterectomy. Hysterectomy rates in Australia are approximately 30,000 per year. Twenty-two percent of hysterectomies in Australia are performed for fibroids, with a further 18% for menorrhagia. The main advantage of hysterectomy is that it treats the problem of fibroids definitively. The disadvantages are the complications associated with surgery: haemorrhage, infection, other organ injury, thromboembolic episodes, deep venous thrombosis and pulmonary embolism; and psychological issues associated with uterus removal and the loss of childbearing potential. Women require approximately 38 days to resume normal activities posthysterectomy.

Uterus sparing
Gonadotropin releasing hormone (GnRH) therapy
is a medical treatment that suppresses oestrogen production, shrinking fibroids and thereby assisting in fibroid removal at hysterectomy. Therapy induces menopausal symptoms and is associated with fibroid regrowth when therapy is ceased.\textsuperscript{7} GnRH therapy is also relatively expensive.

Myomectomy (both laparoscopic and open) enables the removal of fibroids while allowing uterus conservation. A general anaesthetic is required. Adhesions may cause problems postoperatively and the recurrence rate of fibroid regrowth is 10–27%.\textsuperscript{7} Hysteroscopic resection and/or endometrial ablation involves resection of submucous fibroids and endometrial scraping and burning to create amenorrhoea. This can be performed as an outpatient procedure with short recovery times. However, there is a significant recurrence rate of fibroids at 2 years (32\%)\textsuperscript{9} with the majority then managed by hysterectomy. There is also a high rate of adenomyosis (52\%), possibly caused by ablation, which has a negative impact on fertility.

**Uterine artery embolisation**

Uterine artery embolisation (UAE) is a radiological intervention that treats the entire fibroid uterus while preserving the uterus. The procedure was originally performed in the 1980s in Paris to minimise blood loss from larger fibroids during surgery. However, it was discovered that many of these patients were asymptomatic following embolisation. Since 1995, over 25 000 UAEs as treatment for symptomatic fibroids have been performed worldwide.\textsuperscript{10} Fertility rates post-UAE appear similar to patients undergoing myomectomy.\textsuperscript{11}

**The procedure**

Fibroid or uterine artery embolisation is performed as a day procedure by an interventional radiologist. The procedure can be organised through contacting a tertiary referral hospital. It is important for the patient to see a gynaecologist in the work up for UAE to ensure there is no malignant cause of dysmenorrhoea and in the uncommon event of a complication subsequently requiring hysterectomy.

Via the right common femoral artery both left and right uterine arteries are cannulated (Figure 1a, b). Embolisation is performed by injecting polyvinyl alcohol particles until there is a cessation of vascular flow. This results in the infarction of the fibroids and temporary ischaemia of the uterus. The procedure usually takes under 1 hour. The mean radiation exposure in a large series of UAEs performed in the United Kingdom was approximately the same as that incurred in a barium enema.\textsuperscript{3}

**Results**

Post-UAE, fibroids undergo necrosis and will reduce significantly from their original volume, thereby reducing the symptoms associated with the mass effect. It is also believed that removal of vascular engorgement plays a role in the removal of symptoms. Patients undergoing UAE are generally satisfied with the procedure. In a series of 400 UAEs, 97\% of patients were pleased with the outcome and would recommend the treatment to others.\textsuperscript{3}

Hospital stays for the procedure are less than hospital stays for hysterectomy.\textsuperscript{12} For UAEs, stays are usually less than 48 hours,\textsuperscript{7,12} whereas hospital stays for hysterectomy are approximately 6 days.\textsuperscript{7} Postprocedure, women return to normal activities within 14 days and the mean number of days off for women who work outside the home is 10 days, including the procedural day.\textsuperscript{13} Narcotic use for pain relief can be up to 5 days for UAE, however this compares favourably with myomectomy at nearly 9 days.\textsuperscript{14} When comparing myomectomy with UAE, women who underwent UAE reported a complete or significant resolution of menorrhagic symptoms (92\%) versus myomectomy (64\%).\textsuperscript{15}

Uterine artery embolisation pregnancy rates are similar to myomectomy,\textsuperscript{11} however, long term data is lacking. Uterine artery embolisation is more effective than myomectomy in symptom control however, and slightly less effective than hysterectomy. A comparison of outcomes is shown in Table 1.

**Indications for UAE**

Indications for UAE are women with symptoms consistent with fibroid disease and uterine fibroids confirmed by ultrasonography or magnetic resonance imaging (MRI).\textsuperscript{16,20}

**Contraindications**

The absolute contraindications to UAE include active infection, viable pregnancy, and leiomyosarcoma or adnexal malignancy unless it is for palliation. Relative contraindications to UAE include coagulopathy, severe contrast material allergy and renal impairment.\textsuperscript{19}
Complications/adverse events
The largest series to date found an overall peri-procedural complication rate of 8.5% and a 1.25% serious complication rate.\(^\text{19}\) The most common peri-procedural adverse event was pain. This required supplementary therapy as an outpatient or readmission (2.1%).\(^\text{13}\) Complications from UAE include:

- passage of fibroid (most common complication 2.5%)
- postembolisation syndrome (self-limiting cramping pelvic pain, nausea and low-grade temperature related to ischaemia and infarction of the fibroid)
- endometritis
- infection
- premature ovarian failure
- deep venous thrombosis
- pulmonary embolism
- nontarget embolisation
- hysterectomy
- fibroid regrowth.\(^\text{10,13,19}\)

In their review of 25,000 UAEs, Kitamura et al\(^\text{10}\) found only two reported deaths, one caused by sepsicaemia and the other by pulmonary embolus. The US Fibroid Registry, which has logged the outcomes of 3,160 women undergoing UAE, recorded a postprocedure hysterectomy rate of 0.1%.\(^\text{13}\)

Complications from hysterectomy include:

- major haemorrhage (requiring transfusion)
- unintentional organ damage
- pulmonary embolus
- deep venous thrombosis
- major anaesthetic problem
- unintended laparotomy
- infection
- haematoma
- death
- wound dehiscence.\(^\text{21}\)

A comparison of some of the complications is outlined in Table 2.

Follow up
Patients are usually discharged within 24 hours of the procedure. All patients need to be followed up by their general practitioner and radiologist to ensure that there are no complications and to check outcomes. If a patient develops a temperature more than 38°C and if she has increasing pain, she should be admitted to hospital for a septic work up.\(^\text{3}\) It is important to note that fibroid expulsion can occur up to 12 months after the procedure.\(^\text{3}\)

Conclusion

Uterine artery embolisation is an effective treatment for fibroid disease with fewer major complications compared to hysterectomy and myomectomy. Uterine artery embolisation necessitates a shorter hospital stay than myomectomy or hysterectomy. The resumption of normal activities post-UAE occurs in half the time of that for women posthysterectomy. Women report a high level of satisfaction with the procedure. Women in Australia considering their options for the treatment of fibroid disease should be offered UAE as a treatment alternative.

Conflict of interest: none declared.

References

---

**Table 1. Comparison of outcomes\(^\text{15–18}\)**

<table>
<thead>
<tr>
<th>Comparison of outcomes</th>
<th>Hysterectomy</th>
<th>Myomectomy</th>
<th>UAE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bleeding cessation at 6 months</td>
<td>100%</td>
<td>64%</td>
<td>86%</td>
</tr>
<tr>
<td>Bulk/pressure symptoms improvement</td>
<td>80–94%</td>
<td>91%</td>
<td>80–83%</td>
</tr>
<tr>
<td>Pelvic pain improvement</td>
<td>98%</td>
<td>54%</td>
<td>74–84%</td>
</tr>
<tr>
<td>Hospital stay (mean)</td>
<td>2.3–7.3 days</td>
<td>2.9–3.6 days</td>
<td>0–3.6.0 days</td>
</tr>
<tr>
<td>Return to normal activities</td>
<td>33–36 days</td>
<td>36 days</td>
<td>8–14 days</td>
</tr>
<tr>
<td>No further treatment for fibroids</td>
<td>100%</td>
<td>90%</td>
<td>87–99%</td>
</tr>
</tbody>
</table>

**Table 2. Comparison of complications\(^\text{15–18}\)**

<table>
<thead>
<tr>
<th>Comparison of complications</th>
<th>Hysterectomy %</th>
<th>Myomectomy %</th>
<th>UAE %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haemorrhage</td>
<td>1–30</td>
<td>8–13</td>
<td>0</td>
</tr>
<tr>
<td>Thromboembolism</td>
<td>5</td>
<td>2</td>
<td>0.5</td>
</tr>
<tr>
<td>Rehospitalisation and/or re-operation</td>
<td>5–12</td>
<td>3</td>
<td>1–5</td>
</tr>
<tr>
<td>Local infection</td>
<td>10–24</td>
<td>5–31</td>
<td>0–22</td>
</tr>
</tbody>
</table>
Uterine artery embolisation – a treatment alternative for women with fibroids